Status:
UNKNOWN
Evaluation of Remifentanil and Dexmedetomidine in Patients With Noninvasive Mechanical Ventilation Intolerance
Lead Sponsor:
Shanghai Zhongshan Hospital
Conditions:
NIV Intolerance
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
Currently, NIV(Noninvasive ventilation ) is widely used in patients with hypoxemia and atelectasis after cardiac surgery.About 15% of patients have intolerance during NIV. The main manifestation is th...
Eligibility Criteria
Inclusion
- Sign the informed consent form voluntarily and follow the plan requirements;
- Age from 18 to 75 years old (including 18 and 75 years old), regardless of gender;
- Patients who received non-invasive mechanical ventilation after cardiac surgery and were intolerant of non-invasive ventilation.
Exclusion
- A history of allergy to any component of the study drug;
- Visual analogue scale of pain (VAS) score \>4；
- Who had taken dexmedetomidine within 8 hours prior to the study;
- Who had used remifentanil within 2 hours before the study began;
- Expectoration difficulties;
- Women who are pregnant or lactating;
- Coma or uncontrollable convulsions;
- Have a history of mental illness or cognitive impairment;
- Delirium before the study began;
- Patients with severe liver dysfunction (CTP grade C);
- Patients with renal insufficiency (patients receiving renal replacement therapy);
- Preoperative left ventricular ejection fraction (LVEF) \< 30%;
- History of drug and alcohol abuse;
- Other conditions that the investigator deems inappropriate for participation in this clinical trial.
Key Trial Info
Start Date :
March 8 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 28 2023
Estimated Enrollment :
178 Patients enrolled
Trial Details
Trial ID
NCT04734418
Start Date
March 8 2021
End Date
February 28 2023
Last Update
March 16 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, China, 200032